H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH manufacturers
- Davunetide
-
- $0.00 / 1mg
-
2025-12-22
- CAS:211439-12-2
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH Basic information |
| Product Name: | H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH | | Synonyms: | (2S)-5-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid;L-GlutaMine, L-asparaginyl-L-alanyl-L-prolyl-L-valyl-L-seryl-L-isoleucyl-L-prolyl-;ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN FRAGMENT 74-81, MOUSE, RAT;ADNP [74-81];Davunetide;H2N-NAPVSIPQ-OH;H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH;ACTIVITY-DEPENDENT NEUROPROTECTIVE PROTEIN (74-81) (MOUSE, RAT);ACTIVITY-DEPENDENT NEUROPROTECTOR (ADNP) FRAGMENT [HOMO SAPIENS]/[MUS MUSCULUS]/[RATTUS NORVEGICUS] | | CAS: | 211439-12-2 | | MF: | C36H60N10O12 | | MW: | 824.92 | | EINECS: | | | Product Categories: | Peptide | | Mol File: | Mol File |  |
| | H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH Chemical Properties |
| storage temp. | -15°C | | solubility | DMSO:1.0(Max Conc. mg/mL);1.21(Max Conc. mM) | | form | Solid | | color | White to off-white | | Water Solubility | Soluble to 1 mg/ml in water | | Sequence | H-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH |
| | H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH Usage And Synthesis |
| Uses | NAP is a neuroprotective peptide. It can also be used in biological study of integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genes. | | Definition | ChEBI: Davunetide is an oligopeptide. | | Biological Activity | Davunetide (NAPVSIPQ; NAP) is an eight amino acid peptide identified as the active component of activity-dependent neuroprotective protein (ADNP). It has been found to be neuro-protective at femtomolar concentrations in vitro against the neural toxicity of a wide range of compounds. Davunetide has been investigated for Parkinsonμs disease and schizophrenia and in clinical trials for Alzheimnerμs Disease, targeting microtubule-tau Interaction. | | in vivo | Davunetide (2 μg/kg; Intranasally; daily, 5 days a week, for 16 weeks) shows protective effects for central nervous system complications in a diabetes rat model[3]. | Animal Model: | Male Sprague-Dawley rats (Induced by an i.p. streptozotocin (STZ) injection)[3] | | Dosage: | 2 μg/kg | | Administration: | Intranasally beginning on the day following the STZ injection and were given daily, 5 days a week, for 16 weeks | | Result: | Impaired spatial memory of the diabetic rats was observed in the water maze by attenuated learning curve and worsened performance in the probe memory test. Davunetide treatment significantly improved both measurements.
|
| | storage | Store at -20°C |
| | H-ASN-ALA-PRO-VAL-SER-ILE-PRO-GLN-OH Preparation Products And Raw materials |
|